Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States | Centers for Disease Control and Prevention |
---|---|
Centers for Disease Control and Prevention | Officials discuss COVID-19 vaccine deliveries prioritization criteria |
Moderna announces primary efficacy analysis in phase 3 COVE study for its COVID-19 vaccine candidate and filing today with the U.
18Centers for Disease Control and Prevention | V-safe after vaccination health checker |
---|---|
Centers for Disease Control and Prevention | Vaccine Adverse Event Reporting System |
Centers for Disease Control and Prevention.